Drimva

GSK

Vice President - Oncology Clinical Development, Disease Area Head- Hematology

$340K–$568K

Upper Providence +4 · Hybrid (Remote & On-site) · Director · Full-time · Posted Oct 19, 2026

Location
Upper Providence
USA - Massachusetts - Waltham
UK - Hertfordshire - Stevenage
London The Stanley Building
Baar Onyx
Experience
At least 10 years.
Education
Medical degree.

About the job

Leads the clinical development strategy and portfolio delivery for GSK’s hematology oncology assets, from first-in-human studies through regulatory approval and initial launch.

What you'll do

  • Set and oversee clinical development strategy and execution across hematology programs, including trials, translational research, regulatory submissions, and launch readiness.
  • Lead portfolio governance and cross-functional collaboration, managing program progress, risks, and decisions.
  • Manage, mentor, and develop senior clinical development teams and contribute to clinical development standards.

What they ask for

  • Medical degree with board certification or eligibility in oncology.
  • At least 10 years of clinical development experience leading global hematology and oncology programs.
  • Senior clinical and scientific leadership in early- and late-phase oncology drug development, from FTIH through registrational trials and launch readiness.
  • Proven experience delivering late-phase trials and regulatory submissions, and leading geographically dispersed teams and complex multi-stakeholder programs.

Nice to have

  • Clinical background in hematologic malignancies or a hematology subspecialty.
  • Experience with innovative development approaches such as AI/ML, novel trial designs, external data, or real-world data.

Pay

USD 340,500 to USD 567,500 annual base salary

Tools

AI/ML

AI focus

Evaluate and enable AI/ML approaches when they add scientific, operational, or decision-making value to clinical development.

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 6, 2026 (UTC)